Nasdaq to delist OSR Health after bid price compliance failure

Bellevue, Washington - NASDAQ has determined that OSR Health Inc. must be delisted from its platform due to failure to meet the minimum bid price requirement, according to a press release. The company's common stock and warrants will be suspended from trading on The Nasdaq Capital Market starting August 26, 2026. OSR Health plans to appeal the decision before the Nasdaq Independent Hearings Panel.

The company was initially notified of non-compliance on September 5, 2025, and was given two 180-day compliance periods through March 4, 2026, and August 31, 2026. On August 17, 2026, OSR Health experienced its most active share volume, with approximately 370 million shares traded the previous day and 145 million shares the day after.

CEO Peter Hwang stated that the company came within sixteen cents of meeting compliance. Despite utilizing the second compliance period, a timely hearing request will not prevent the trading suspension. There is no guarantee that the panel will grant the company's request for continued listing or reinstatement of trading. OSR Health is a global healthcare holding company focused on immuno-oncology, regenerative biologics, and medical device technologies through its subsidiaries.